Immunocore/$IMCR
1D1W1MYTD1Y5YMAX
Capital at risk
About Immunocore
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
- Ticker
- $IMCR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 524
- Headquarters
- Abingdon, United Kingdom
- Website
- www.immunocore.com
Immunocore Metrics
BasicAdvanced
$1.8B
-
-$0.36
0.74
-
Price and volume
Market cap
$1.8B
Beta
0.74
52-week high
$40.71
52-week low
$27.56
Average daily volume
394K
Financial strength
Current ratio
4.469
Quick ratio
4.148
Long term debt to equity
103.157
Total debt to equity
103.611
Interest coverage (TTM)
-0.23%
Profitability
EBITDA (TTM)
0.756
Gross margin (TTM)
32.87%
Net profit margin (TTM)
-4.20%
Operating margin (TTM)
-0.66%
Effective tax rate (TTM)
-561.57%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-0.16%
Return on equity (TTM)
-4.47%
Valuation
Price to revenue (TTM)
4.16
Price to book
4.34
Price to tangible book (TTM)
4.34
Price to free cash flow (TTM)
-42.809
Free cash flow yield (TTM)
-2.34%
Free cash flow per share (TTM)
-0.826
Growth
Revenue change (TTM)
20.95%
Earnings per share change (TTM)
-13.06%
3-year revenue growth (CAGR)
25.19%
3-year earnings per share growth (CAGR)
-34.44%
What the Analysts think about Immunocore
Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Analyst projections of the future price of Immunocore stock.
Bulls say / Bears say
KIMMTRAK net revenues grew 18% year-over-year to $115.9 million in Q2 2026, demonstrating robust commercial momentum across the US, Europe, and international markets. (FT Markets)
Immunocore achieved a net income of $12.2 million for the six months ended June 30, 2026, compared to a $5.3 million loss in the prior year, marking its first half-year profitability. (MarketScreener)
Pipeline diversification strengthened at IAS 2026, where IMC-M113V HIV trial data showcased robust type I and II interferon-associated immune responses and durable viral control, highlighting the platform’s extension into infectious diseases. (Immunocore Press Release)
Q2 2026 EPS missed analysts’ expectations, with a $0.02 loss per share versus a consensus loss of $0.01, indicating near-term profitability pressures. (MarketBeat)
Research and development expenses rose 7.2% year-over-year to $73.9 million in Q2 2026 as Immunocore advances multiple Phase 3 trials, increasing operational cash burn and narrowing margins. (Immunocore Press Release)
Management disclosed that approximately $6 million of Q2 sales derived from distributor inventory stocking, which is expected to create a headwind in Q3 2026, raising concerns about underlying demand sustainability. (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2026.
Immunocore Financial Performance
Revenues and expenses
Immunocore Earnings Performance
Company profitability
Upcoming events
No upcoming events
Immunocore News
AllArticlesVideos
Funds containing Immunocore
AllUSDGBP
Fund name | Fund size | $IMCR weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.